Free shipping on all orders over $ 500

Zotarolimus

Cat. No. M6130
Zotarolimus Structure
Synonym:

ABT-578

Size Price Availability Quantity
2mg USD 110 In stock
5mg USD 160 In stock
10mg USD 220 In stock
25mg USD 420 In stock
Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

In vitro: Zotarolimus (ABT-578) is a semi-synthetic analogue of rapamycin, made by substituting a tetrazole ring for the native hydroxyl group at position 42 in rapamycin. Zotarolimus is highly effective in inhibiting both smooth muscle cell and endothelial cell proliferation, with IC50 values of 2.9 nM and 2.6 nM, respectively. Zotarolimus is mechanistically similar to sirolimus in having high-affinity binding to the immunophilin FKBP12 and comparable potency for inhibiting in vitro proliferation of both human and rat T cells. Zotarolimus inhibits Con A-induced human T cells and rat T cells proliferation with IC50 of 7.0 nM and 1337 nM respectively. In vivo: Zotarolimus-eluting stents effectively reduce neointima formation in a 28-day, well-characterized swine model of coronary artery restenosis. Zotarolimus appears effective in preventing neointimal thickening, reducing late loss from 1.03 to 0.62 mm with a 47% reduction in TVF compared with bare metal stents (15.4% with the Driver stent to 8.1% with the Endeavor stent). Zotarolimus is efficacious in suppressing adjuvant DTH, EAE, and cardiac allograft rejection with ED50 values of 1.72, 1.17, and 3.71 mg/kg/day, respectively.

Protocol
Cell Experiment
Cell lines Human coronary artery cells
Preparation method Cell proliferation is assayed by measuring tritiated thymidine incorporation in vitro. Human coronary artery cells (hCa) are seeded into tissue culture flasks for expansion and applied to 96-well plates at desired density in complete media (5000 hCaSMC; 10 000 hCaEC). After 2 days, complete media is replaced with incomplete media to synchronize cells and induce G0 state. Two days later, incomplete media are removed and replaced with complete media (serum/growth factors) to induce G0 to G1 transition. Complete media also contain drug at desired concentrations to determine its effects on cell proliferation. On day 7, 3H-thymidine is added to cells to monitor DNA synthesis, and cells are harvested after overnight incorporation of radioactivity. After an incubation period of 72 h, 25 μL (1 μCi/well) of 3H-thymidine are added to each well. The cells are incubated at 37°C for 16-18 h to allow for incorporation of 3H-thymidine into newly synthesized DNA and the cells harvested onto 96-well plates containing bonded glass fibre filters . The filter plates are air-dried overnight, MicroScint-20 (25 μL) added to each filter well and counted. Drug activity is determined by the inhibition of 3H-thymidine incorporation into newly synthesized DNA relative to cells grown in complete media.
Concentrations ~1 μM
Incubation time 5 days
Animal Experiment
Animal models Male Sprague-Dawley rats
Formulation ethanol: propylene glycol: cremophor EL: D5W vehicle (20: 30: 2: 48, by volume)
Dosages 2.5 mg/kg
Administration intravenous or oral
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 966.21
Formula C52H79N5O12
CAS Number 221877-54-9
Purity >99%
Solubility 100 mg/mL in DMSO
Storage at -20°C
References

Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial.
Iqbal J, et al. Circ Cardiovasc Interv. 2015 Jun;8(6):e002230. PMID: 26047993.

Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
Valgimigli M, et al. J Am Coll Cardiol. 2015 Mar 3;65(8):805-15. PMID: 25720624.

Related mTOR Products
LY303511

LY303511 is a structural analogue of LY294002, which does not inhibit PI3K, increased homotypic GJIC.

Temsirolimus

Temsirolimus (CCI-779) is a specific mTOR inhibitor with IC50 of 1.76 μM.

WYE-125132

WYE-125132 is a highly potent, ATP-competitive mTOR inhibitor with IC50 of 0.19 nM; highly selective for mTOR versus PI3Ks or PI3K-related kinases hSMG1 and ATR.

AZD2014

AZD2014 is a novel dual mTORC1 and mTORC2 inhibitor with potential antineoplastic activity.

Torin 1

Torin 1 is a potent and selective inhibitor of mTOR with IC50 of 2 and 10 nM for mTORC1 and mTORC2, respectively.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Zotarolimus, ABT-578 supplier, mTOR, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.